Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis, asthma, and CRSwNP as core indications. Learn ...

For the first time, Eupraxia is reporting 24-week data on symptom response from the highest dose cohort in the open label, Phase 1b/2a portion of ...

Detailed price information for Eupraxia Pharmaceuticals Inc (EPRX-Q) from The Globe and Mail including charting and trades.

Seasonal allergies are nothing to sniff at. Spring allergy season is worsening with each passing year, as winds carrying ...

Eupraxia Pharmaceuticals Inc. (EPRX) garnered retail attention on Tuesday after the biotech company reported positive data ...

Mr. James brings more than 20 years of biopharmaceutical leadership experience, with deep expertise in capital markets, investor relations, and corporate strategy, serving in senior executive roles at ...

A Topeka boy is marking what may be one of the rarest birthdays in the city this week, turning 13 years old on March 13 — having been born on March 13, 2013.

Leading allergy medical societies and patient advocacy groups highlight path forward to advance food allergy prevention, treatment, and managementWashington, DC, March 19, 2026 (GLOBE NEWSWIRE) -- The ...

BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated dosing in KT-579 ...

Scientists from Great Ormond Street Hospital (GOSH) and University College London (UCL) have created the first lab‑grown esophagus—the food pipe—shown to safely replace a full section of the organ and ...

Colon cancer is one of the most common cancers in the U.S., with more than 100,000 cases diagnosed each year. But some people ...

Among children, adolescents and adults with peanut allergy, a once-daily peanut sublingual immunotherapy tablet was well tolerated up to the highest dose in an up-dosing regimen, according to phase ...